CMS Proposes Letting Part D Plans Switch Biologics To Non-Interchangeable Biosimilars

By Gabrielle Wanneh / November 6, 2023 at 7:02 PM

In a bid to boost uptake of lower-cost biosimilars, CMS is proposing to let Medicare Part D plans substitute reference biologics with biosimilars that haven’t been deemed interchangeable by FDA.



Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.